This issue of Hematology/Oncology Clinics will focus on The Treatment of Myeloid Malignancies with Kinase Inhibitors. Articles will focus on: Targeting aberrant signaling in myeloid malignancies: promise versus reality; The development and use of imatinib for the treatment of chronic myelogenous leukemia; Mechanisms of resistance to ABL kinase inhibition in CML and the development of next generation ABL kinase inhibitors; Tyrosine kinase inhibitors in the treatment of systemic mastocytosis and hypereosinophilic syndrome; The development and use of JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPN); Mechanisms of resistance to JAK2 inhibitors in MPN; Kinase inhibitor screening in myeloid malignancies; and more!
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. viii 7. Preface - p. ix 8. Targeting Aberrant Signaling in Myeloid Malignancies: Promise Versus Reality - p. 565 9. Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia - p. 577 10. Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors - p. 589 11. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms - p. 613 12. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms - p. 627 13. Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis - p. 643 14. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia - p. 663 15. Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment - p. 681 16. Kinase Inhibitor Screening in Myeloid Malignancies - p. 693 17. Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms - p. 705
No hay muestra disponible
No hay ficha técnica disponible
This issue of Hematology/Oncology Clinics will focus on The Treatment of Myeloid Malignancies with Kinase Inhibitors. Articles will focus on: Targeting aberrant signaling in myeloid malignancies: promise versus reality; The development and use of imatinib for the treatment of chronic myelogenous leukemia; Mechanisms of resistance to ABL kinase inhibition in CML and the development of next generation ABL kinase inhibitors; Tyrosine kinase inhibitors in the treatment of systemic mastocytosis and hypereosinophilic syndrome; The development and use of JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPN); Mechanisms of resistance to JAK2 inhibitors in MPN; Kinase inhibitor screening in myeloid malignancies; and more!
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. viii 7. Preface - p. ix 8. Targeting Aberrant Signaling in Myeloid Malignancies: Promise Versus Reality - p. 565 9. Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia - p. 577 10. Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors - p. 589 11. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms - p. 613 12. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms - p. 627 13. Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis - p. 643 14. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia - p. 663 15. Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment - p. 681 16. Kinase Inhibitor Screening in Myeloid Malignancies - p. 693 17. Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms - p. 705
No hay muestra disponible
No hay ficha técnica disponible
